Chinese Journal of Cancer Research

, Volume 15, Issue 2, pp 92–97 | Cite as

Effects ofin vivo gene transduction of anti-MDR1 ribozyme in combination with chemotherapy on multidrug-resistant human lymphoma growth in mice

  • Xu Dong-ping 
  • Wang Fu-sheng 
  • Ohnuma Takao
  • Jin Lei 


Objective: To study the effect of adenovirus- mediated transfer of anti-MDR1 ribozyme on the reversal of multidrug resistant (MDR) phenotype of P-glycoprotein (P-gp)-positive Daudi human Burkitt lymphoma bothin vitro andin vivo. Methods: A recombinant adenovirus expressing 196Rz (Adv-196Rz) was developed and functionally evaluated. SCID mice inoculated subcutaneously (s.c.) with 5×l06 Daudi/MDR20 cells were locally treated with Adv-196Rz or mock virus (Adv-Mock) at the multiplicity of infection (MOI) of 400 PFU once a day for 3 consecutive days. Then the mice were intraperitoneally (i.p.) administrated with vincristine (VCR) 450ng/g for 5 consecutive days. Results:In vitro employment of Adv-196Rz was able to interruptMDR1 transcription, to inhibit P-gp expression and to restore drug sensitivity to VCR of Daudi/MDR20 cells.In vivo, 87.5% (7/8) of Daudi/MDR20-inoculated mice treated with Adv-Mock+ VCR developed palpable tumor by the 6th week and died or were sacrificed (because of tumor weight >10% of body weight) by the 11th week. In contrast, among 9 Daudi/MDR20-inoculated mice treated with Adv-196Rz + VCR, only 3 developed tumor by the 11th, 13th and 14th week, respectively. 66.7% of mice survived >120 days in tumor-free. The survival difference between the two groups was very significant (P<0.01). Conclusion: Adenovirus-mediated Transfer of 196Rz can revert drug resistance of MDR tumor cells bothin vitro andin vivo. Adv-196Rz may prove useful as an adjuvant in the chemotherapy of P-gp mediated MDR human tumors.

Key words

MDR Ribozyme Cancer Gene therapy 

CLC number



Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. [1]
    Bellamy WT. P-glycoproteins and multidrug resistance[J]. Ann Rev Pharmacol Toxicol 1996; 36: 161–83.CrossRefGoogle Scholar
  2. [2]
    Ross DD. Novel mechanisms of drug resistance in leukemia[J]. Leukemia 2000; 14: 467–73.PubMedCrossRefGoogle Scholar
  3. [3]
    Stavrovskaya AA. Cellular mechanisms of multidrug resistance of tumor cells[J]. Biochemistry (Mosc) 2000; 6: 95–106.Google Scholar
  4. [4]
    Wang FS, Kobayashi H, Liang KW, et al. Retrovirus-mediated transfer of anti-MDR1 ribozymes fully restores chemosensitivity of P-glycoprotein- expression human lymphoma cells[J]. Hum Gene Ther 1999; 10: 1185–95.PubMedCrossRefGoogle Scholar
  5. [5]
    Wang Fu-sheng, Jin Lei, Lei Zhou-yun, et al. Anti-MDR ribozymes mediated by retroviral vector efficiently reverse the multidrug resistance in resistant human lymphoma Daudi cells(in Chinese) [J]. Chin J Cancer Biother2000;7:94–7.Google Scholar
  6. [6]
    Wang Fu-sheng, Lei Zhou-yun, Jin Lei, et al. Synthesis of chimeric anti-MDRl ribozymes and their biological activities in cell-free system(in Chinese)[J]. Chin J Oncol 2000; 22: 184–8.Google Scholar
  7. [7]
    Becker, TC, Noel RJ, Coats WS, et al. Use of recombinant adenovirus for metabolic engineering of mammalian cells[J]. Methods Cell Biol 1994; 43: 161–89.PubMedCrossRefGoogle Scholar
  8. [8]
    Dorai T, Perlman H, Walsh K, et al. A recombinant defective adenoviral agent expressing anti-bcl-2 ribozyme promotes apoptosis of bel-2-expressing human prostate cancer cells[J]. Int J Cancer 1999; 82: 846–52.PubMedCrossRefGoogle Scholar
  9. [9]
    Kobayashi H, Takemura Y, Ohnuma T. Relationship between tumor cell density and drug concentration and the cytotoxic effects of doxorubicin or vincristine: mechanism of inoculum effects [J]. Cancer Chemother Pharmacol 1992; 31: 6–10.PubMedCrossRefGoogle Scholar
  10. [10]
    Kobayashi H, Dorai T, Holland JF, et al. Reversal of drug sensitivity in multidrug-resistant tumor cells by an MDR1 (PGYI) ribozyme[J]. Cancer Res 1994; 54: 1271–5.PubMedGoogle Scholar
  11. [11]
    Gao Z, Gao Z, Fields JZ, et al. Tumor-specific expression of anti-mdr1 ribozyme selectively restores chemosensitivity in multidrug-resistant colon-adenocarcinoma cells[J]. Int J Cancer 1999; 82: 364–52.CrossRefGoogle Scholar
  12. [12]
    Nagata J, Kijima H, Hatanaka H, et al. Reversal of drug resistance using hammerhead ribozymes against multidrug resistance-associated protein and multidrug resistance 1 gene[J]. Int J Oncol 2002; 21: 1021–6.PubMedGoogle Scholar
  13. [13]
    Van Tendeloo VF, Van Broeckhoven C, Berneman ZN, et al. Gene therapy: principles and applications to hematopoietic cells[J]. Leukemia 2001; 15: 545–58.PubMedCrossRefGoogle Scholar
  14. [14]
    Li L, Wickham TJ, Keegan AD. Efficient transduction of murine B lymphocytes and B lymphoma lines by modified adenoviral vectors: enhancement via targeting to FcR and heparan-containing proteins [J]. Gene Ther 2001; 8: 938–45.PubMedCrossRefGoogle Scholar
  15. [15]
    Buttgereit P, Weineck S, Ropke G, et al. Efficient gene transfer into lymphoma cells using adenoviral vectors combined with lipofection[J]. Cancer Gene Ther 2000; 7: 1145–55.PubMedCrossRefGoogle Scholar
  16. [16]
    Buttgereit P, Schakowski G, Marten A, et al. Effects of adenoviral wild-type p53 gene transfer in p53-mutated lymphoma cells[J]. Cancer Gene Ther 2001; 8: 430–9.PubMedCrossRefGoogle Scholar

Copyright information

© Chinese Journal of Cancer Research 2003

Authors and Affiliations

  • Xu Dong-ping 
    • 1
  • Wang Fu-sheng 
    • 1
  • Ohnuma Takao
    • 2
  • Jin Lei 
    • 1
  1. 1.Department of BioengineeringThe Institute of Infectious Diseases PLABeijingChina
  2. 2.Division of Medical OncologyMount Sinai School of MedicineNew YorkUSA

Personalised recommendations